CD22 and precursor B-cell acute lymphoblastic leukemia: Several meta-analyses demonstrated that remission rates of B-ALL and B-NHL patients treated with CD19/CD22 multispecific CAR T-cells were not substantially improved when compared to treatment with single-targeting CAR T-cells (42, 43).